AIMS/HYPOTHESIS: The aim of this study was to investigate the association of N-terminal pro-brain natriuretic peptide (NT-proBNP) with traditional cardiovascular risk factors and incident cardiovascular events in older people with type 2 diabetes. METHODS: In the prospective phase of the Edinburgh Type 2 Diabetes Study, 1066 men and women aged 60 to 75 years with type 2 diabetes mellitus were followed for 4 years; 112 participants had an incident cardiovascular event. At baseline, cardiovascular risk factors, pre-existing cardiovascular disease and levels of NT-proBNP were evaluated. RESULTS: Raised plasma NT-proBNP levels were associated with these classical cardiovascular risk factors: increased duration of diabetes, use of insulin, raised BMI, reduced HDL-cholesterol, reduced renal function and use of lipid-lowering and anti-hypertensive medication (all p < 0.05). In the prospective analysis, NT-proBNP was strongly associated with subsequent risk of all cardiovascular disease events (HR per one SD increase in NT-proBNP 1.39; 95% CI 1.10, 1.75), independent of cardiovascular risk factors traditionally used to predict vascular events. NT-proBNP was also independently associated with incident coronary artery disease events (1.48, 95% CI 1.10, 1.98). The addition of NT-proBNP to multivariate models improved the C-index by 0.019 for the 'hard' cardiac endpoint (fatal and non-fatal myocardial infarction). CONCLUSIONS/ INTERPRETATION: In older people with type 2 diabetes, NT-proBNP is associated with the development of coronary and cerebrovascular events, independent of a wide range of other vascular and metabolic risk factors, and may prove a useful addition to current vascular risk scores in diabetes populations.
AIMS/HYPOTHESIS: The aim of this study was to investigate the association of N-terminal pro-brain natriuretic peptide (NT-proBNP) with traditional cardiovascular risk factors and incident cardiovascular events in older people with type 2 diabetes. METHODS: In the prospective phase of the Edinburgh Type 2 Diabetes Study, 1066 men and women aged 60 to 75 years with type 2 diabetes mellitus were followed for 4 years; 112 participants had an incident cardiovascular event. At baseline, cardiovascular risk factors, pre-existing cardiovascular disease and levels of NT-proBNP were evaluated. RESULTS: Raised plasma NT-proBNP levels were associated with these classical cardiovascular risk factors: increased duration of diabetes, use of insulin, raised BMI, reduced HDL-cholesterol, reduced renal function and use of lipid-lowering and anti-hypertensive medication (all p < 0.05). In the prospective analysis, NT-proBNP was strongly associated with subsequent risk of all cardiovascular disease events (HR per one SD increase in NT-proBNP 1.39; 95% CI 1.10, 1.75), independent of cardiovascular risk factors traditionally used to predict vascular events. NT-proBNP was also independently associated with incident coronary artery disease events (1.48, 95% CI 1.10, 1.98). The addition of NT-proBNP to multivariate models improved the C-index by 0.019 for the 'hard' cardiac endpoint (fatal and non-fatal myocardial infarction). CONCLUSIONS/ INTERPRETATION: In older people with type 2 diabetes, NT-proBNP is associated with the development of coronary and cerebrovascular events, independent of a wide range of other vascular and metabolic risk factors, and may prove a useful addition to current vascular risk scores in diabetes populations.
Authors: Lars Rydén; Peter J Grant; Stefan D Anker; Christian Berne; Francesco Cosentino; Nicolas Danchin; Christi Deaton; Javier Escaned; Hans-Peter Hammes; Heikki Huikuri; Michel Marre; Nikolaus Marx; Linda Mellbin; Jan Ostergren; Carlo Patrono; Petar Seferovic; Miguel Sousa Uva; Marja-Riita Taskinen; Michal Tendera; Jaakko Tuomilehto; Paul Valensi; Jose Luis Zamorano; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Cetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Guy De Backer; Per Anton Sirnes; Eduardo Alegria Ezquerra; Angelo Avogaro; Lina Badimon; Elena Baranova; Helmut Baumgartner; John Betteridge; Antonio Ceriello; Robert Fagard; Christian Funck-Brentano; Dietrich C Gulba; David Hasdai; Arno W Hoes; John K Kjekshus; Juhani Knuuti; Philippe Kolh; Eli Lev; Christian Mueller; Ludwig Neyses; Peter M Nilsson; Joep Perk; Piotr Ponikowski; Zeljko Reiner; Naveed Sattar; Volker Schächinger; André Scheen; Henrik Schirmer; Anna Strömberg; Svetlana Sudzhaeva; Juan Luis Tamargo; Margus Viigimaa; Charalambos Vlachopoulos; Robert G Xuereb Journal: Eur Heart J Date: 2013-08-30 Impact factor: 29.983
Authors: Michael H Olsen; Tine W Hansen; Marina K Christensen; Finn Gustafsson; Susanne Rasmussen; Kristian Wachtell; Hans Ibsen; Christian Torp-Pedersen; Per R Hildebrandt Journal: Eur Heart J Date: 2007-01-22 Impact factor: 29.983
Authors: Michael Resl; Stephanie Neuhold; Michaela Riedl; Heidemarie Abrahamian; Guido Strunk; Rudolf Prager; Martin Clodi; Martin Hülsmann; Anton Luger; Richard Pacher Journal: Eur J Cardiovasc Prev Rehabil Date: 2011-02-22
Authors: Thomas J Wang; Martin G Larson; Daniel Levy; Emelia J Benjamin; Eric P Leip; Torbjorn Omland; Philip A Wolf; Ramachandran S Vasan Journal: N Engl J Med Date: 2004-02-12 Impact factor: 91.245
Authors: S Goya Wannamethee; Paul Welsh; Gordon D Lowe; Vilmundur Gudnason; Emanuele Di Angelantonio; Lucy Lennon; Ann Rumley; Peter H Whincup; Naveed Sattar Journal: J Am Coll Cardiol Date: 2011-06-28 Impact factor: 24.094
Authors: Graham S Hillis; Paul Welsh; John Chalmers; Vlado Perkovic; Clara K Chow; Qiang Li; Min Jun; Bruce Neal; Sophia Zoungas; Neil Poulter; Giuseppe Mancia; Bryan Williams; Naveed Sattar; Mark Woodward Journal: Diabetes Care Date: 2013-10-02 Impact factor: 19.112
Authors: Paul Welsh; Orla Doolin; Peter Willeit; Chris Packard; Peter Macfarlane; Stuart Cobbe; Vilmundur Gudnason; Emanuele Di Angelantonio; Ian Ford; Naveed Sattar Journal: Eur Heart J Date: 2012-08-31 Impact factor: 29.983
Authors: C M Parrinello; K Matsushita; M Woodward; L E Wagenknecht; J Coresh; E Selvin Journal: Diabetes Obes Metab Date: 2016-06-14 Impact factor: 6.577
Authors: Bernt Johan von Scholten; Henrik Reinhard; Tine Willum Hansen; Morten Lindhardt; Claus Leth Petersen; Niels Wiinberg; Peter Riis Hansen; Hans-Henrik Parving; Peter Karl Jacobsen; Peter Rossing Journal: Cardiovasc Diabetol Date: 2015-05-21 Impact factor: 9.951
Authors: Suriya Prausmüller; Michael Resl; Henrike Arfsten; Georg Spinka; Raphael Wurm; Stephanie Neuhold; Philipp E Bartko; Georg Goliasch; Guido Strunk; Noemi Pavo; Martin Clodi; Martin Hülsmann Journal: Cardiovasc Diabetol Date: 2021-02-02 Impact factor: 9.951
Authors: Mohammad Ziaul Islam Chowdhury; Fahmida Yeasmin; Doreen M Rabi; Paul E Ronksley; Tanvir C Turin Journal: BMJ Open Date: 2019-08-30 Impact factor: 2.692